Who
Brian Goff
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Agios Pharmaceuticals; Director, Intellia Therapeutics; EVP & Chief Commercial Officer, Alexion Pharmaceuticals; EVP and President, Hematology, Baxalta.
In numbers
- Trades disclosed
- 150
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $7.5M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Jul 2015
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —25,528 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $433K12,472 at $34.71 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —13,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,528 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $229K6,596 at $34.71 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,528 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —25,528 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $433K12,472 at $34.71 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —13,500 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $229K6,596 at $34.71 | filing |
News
Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Brian Goff; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.